Subcutaneous amivantamab plus lazertinib may offer a survival benefit over intravenous administration, alongside dramatically reduced administration times, a new study suggests.
KIRKLAND, QC, and MISSISSAUGA, ON, Dec. 21, 2023 /CNW/ - Merck , known as MSD outside the United States and Canada, and Eisai announce that KEYTRUDA®, Merck s anti-PD-1 therapy, plus LENVIMA®, an.
Natasha B. Leighl, BSc, MMSc, MD, discusses efficacy findings with the EGFR/MET inhibitor amivantamab in patients with advanced non–small cell lung cancer harboring MET exon 14 skipping mutations.
A long-term post-hoc analysis from the JAVELIN Bladder 100 trial demonstrated that first-line maintenance avelumab elicited similar overall survival and progression-free survival benefits vs best supportive care alone in patients with advanced urothelial carcinoma.
Adding stereotactic body radiation therapy (SBRT) to treatment with sorafenib improved overall survival and progression-free survival as well as quality of life.